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If channel inhibitor. Ivabradine is a selective antagonist of funny
channels with anti-anginal and anti-ischaemic properties that
provides pure heart rate reduction, reducing the diastolic depolar-
ization slope, without altering other cardiac and haemodynamic
parameters. There is consistent evidence that ivabradine is effective
in reducing angina pectoris symptoms and myocardial ischemia. At
approved doses ivabradine is safe, improves exercise performance
and reduces heart rate has a positive effect on heart rate. Available
literature supports its use in the management of patients with stable
CAD and chronic HF. Recent studies have casted doubts on the safety
of non approved high doses of ivabradine for the treatment of
patients with CAD and without clinical HF, but have shown no
concerns on the doses approved for clinical use.
Gene therapy. Therapeutic angiogenesis has been focused on the
administration of the vascular endothelial growth factor (VEGF) and
ﬁbroblast growth factor (FGF). At present, VEGF and FGF have been the
most extensively studied angiogenic agents. Growth factor proteins may
be given directly or through gene-based approaches using naked
plasmid deoxyribonucleic acid or a viral vector that encodes the gene
so that it can be taken up by the recipient endothelial cells. These agents
may be administered directly to the myocardium by epicardial,
endocardial, or intracoronary injection. The studies using these agents
have so far achieved inconclusive results.
Enhanced external counterpulsation. EECP is a novel treatment
for patients with ischemic heart disease and refractory angina. EECP
is performed by encircling the legs with compression devices that
inﬂate during diastole to 300 mm Hg and deﬂate them during
systole. This counterpulsation unloads the left ventricle during
ventricular systole and improves coronary blood ﬂow during
diastole. In a randomised clinical trial 139 patients clinical symptoms
and treadmill exercise times improved and a variable effect on
myocardial perfusion was found. However, the absence of proper
blinding during this study makes the results uncertain.
Spinal cord stimulation. Spinal cord stimulation, is an effective
method for pain relief in patients with refractory angina not
amenable to revascularisation. The treatment involves placing a
stimulating electrode in the dorsal epidural space at the C7–T1 level.
It has been suggested that spinal cord stimulation exerts beneﬁcial
effects by decreasing pain and sympathetic tone. Early study with
spinal cord stimulators suggested an improvement in total exercise
time and time to angina. However, in another trial the anginal
symptoms decreased even after discontinuation of therapy suggest-
ing a most likely primary analgesic effect of this treatment.
Despite signiﬁcant advances in the percutaneous treatment of
coronary artery disease medical management represents the treat-
ment of choice in most patients. Newer therapeutic agents have been
shown to be safe and effective when used in monotherapy or in
association with the existing classical antianginals.
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Abstract
Obesity is a key factor in the development of insulin resistance
(IR), cardiovascular disease, hypertension, type 2 diabetes etc. Given
the near epidemic incidence of obesity in western society there is a
clear need for effective treatment options. Mineralocorticoid receptor
(MR) blockade has shown signiﬁcant promise in transgenic mouse
models of obesity in limiting IR and adipocyte dysfunction, a disease
that is independent of classical MR actions (renal). Female 10-week-
old C57bl6 mice were fed with normal chow or a high fat (HF) diet
for 12 weeks. Mice fed HF diet were concomitantly treated for
12 weeks with drospirenone (DRSP, 6 mg/kg/day), a potent MR
antagonist with antiadipogenic activity, or spironolactone (SPIRO,
20 mg/kg/day). Mice fed HF diet showed a signiﬁcant increase in
total body weight, fat mass, mean adipocyte size, expression of white
adipose tissue (WAT) marker genes and showed impaired glucose
tolerance after intraperitoneal plasma glucose tolerance test. DRSP
and SPIRO prevented weight gain and white fat mass expansion
induced by HF diet in parametrial, perivescical, and inguinal depots
without affecting interscapular fat pad weight. Magnetic Resonance
Imaging (MRI) conﬁrmed that MR antagonists blocked the HF diet-
driven expansion of abdomino-pelvic (parametrial and perivescical)
fat volume. High levels of MR mRNA were detected in all depots of
adipose tissue. HF fed mice showed no increase in heart or kidney
weight and tissue ﬁbrosis. Cardiac macrophage recruitment and
osteopontin staining was increased in hearts of HF fed mice and
reversed by both MR antagonists. Moreover, both DRSP and SPIRO
prevented the impaired glucose tolerance in mice fed HF diet, and
countered HF diet-induced up-regulation of WAT markers transcripts
and adipocyte hypertrophy. Importantly, MR antagonists increased
uncoupling protein 1 (UCP-1) positive brown-like adipocyte content
in WAT, and improved metabolic activity of adipose tissue, as
indicated by PET/CT imaging. In keeping with this, MR antagonism
signiﬁcantly increased expression of brown-like adipocyte marker
genes such PRDM16, CIDEA, beta-3 adrenergic receptor (ADRB3) and
UCP-1 in all WAT depots analysed. In exploring the mechanism, we
demonstrated that MR antagonism induced brown adipose tissue
(BAT) markers, and reduced the autophagic rate, a key remodelling
process in adipocyte differentiation, in WAT depots in vivo as well as
in primary cultured adipocytes. We conclude that adipocyte MR
regulates BAT-like remodeling of WAT through modulation of
autophagy. MR blockade therefore has promise as a novel therapeu-
tic option for the prevention of metabolic dysfunctions and the
cardiac consequences of obesity.
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In clinical trials, mineralocorticoid receptor (MR) antagonists
decrease cardiovascular ischemia and mortality suggesting a beneﬁ-
cial role of MR inhibition in the vasculature. We have shown that
human coronary and umbilical endothelial cells (HUVEC) express
functional MR. In endothelial cells MR activation by aldosterone
promoted transcription of ICAM-1. Most importantly cell adhesion
assays demonstrated that aldosterone promotes leukocyte adhesion
to ECs, an effect that was inhibited by spironolactone and ICAM-1
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